We’ve sliced and diced our portfolio into distinct “trends” that define our edge.
We are pleased to report that as of April 2021 the SOSV Climate Tech 100 have raised $1.85 billion from investors and have a market cap of $5.65 billion. The average company is four years old. SOSV (our parent fund) has invested $89 million in these companies and was in most cases the first investor, though we continued investing through early rounds.
IndieBio has never been one to shy away from the riskiest and most impactful investments for our planet. In fact, we embrace them.
Boosting female representation in the startup world is an ongoing challenge, but we’re dedicated to gender balance, not only because it’s the right thing to do, but because we would be dismissing impressive companies otherwise. We’ve found that more gender balance leads to better workplace culture and better ideas being exchanged.
Future of Food
It’s not just that we can make meat and fish in the lab, or with mushrooms and chickpeas. It’s not just that AI can predict the best plant ingredients to make the best tasting milk and yogurt. And it’s not just that yeast can be fermented to produce the healthier and better food preservatives. We’re diving deep every day into the foods that will satisfy novelty-seekers and conventionalists alike.
We’re putting big bets on the newest technologies and trends we think are ahead of the curve.
Future of Medicine
Medicine ain’t what it used to be. Today, bloodletting, skull-drilling and giving children cocaine for toothaches are relics of the past. Tomorrow, so too will addictive opioids, chemotherapy, and psychiatric drugs that are non-selectively bathing our bodies in chemicals.
The future of medicine is an exciting one, and we’re excited to share the most exciting technologies that enable the next wave of medicine and healthcare.
Our mission has always been Human and Planetary Health from the beginning, so it’s hard to say which of our companies are “impact” companies (in some ways, they all are).
Here, we narrowed down the startups that are directly addressing sustainability issues, improving public health, mitigating inequality, and democratizing access to infrastructure and technologies.
Every season of the year, a new batch and about one-sixth of our alumni are in raise mode. These companies are currently raising and would love to talk to interested investors. We can set up those meetings or you can contact the companies directly.
In the field of liquid biopsy, the abundance of new technologies are mere screening tests. They can’t monitor patients’ progression and drive clinical decisions. The real money is in monitoring disease patients, for years. Atomic Force Microscopy scans the surface of cells at such high resolution that it can not only discriminate cancer cells from […]
Potassium controls every single heartbeat you have, but it’s the kidneys that control your potassium levels. You could say the kidneys are the gatekeeper to your heart. Kidney care is going through dramatic market disruption. Home dialysis is displacing clinics. And patient care management companies are siphoning off patients. Nevertheless, these patients are still ending […]
Modern lifestyles are hard on our livers and kidneys, the organs that filter and break down metabolic waste products. But people don’t want to take drugs – they want to get healthy. Unlock unleashes the power of the microbiome to help out. Unlocked is a consumer probiotic company that unlocks silent genes – regaining the […]
RizLab Health is addressing the pandemic of antimicrobial resistance and helping clinicians by pinpointing the source of infection (and thus preventing inappropriate antibiotic prescriptions) with their point-of-care device, the CytoTracker. The CytoTracker differentiates bacterial from viral infection profiles within minutes using only a single drop of blood. A 200-person clinical study demonstrated the CytoTracker beats […]
The cosmetic effects of ageing on skin and the development of skin cancers result from multiple changes in three types of skin cells (fibroblasts, keratinocytes, melanocytes) and degeneration of extracellular components (collagen, elastin). These changes are accelerated by toxic chemicals that are produced in skin when it is exposed to all wavelengths of sunlight, all […]
Biological sample preparation has not kept pace with the dramatic changes in analytical techniques. Nowhere is this more evident than in DNA sample prep, which continues to be a low throughput process serving high throughput next-generation DNA sequencing. This mismatch is limiting the accelerated uptake of next generation sequencing. Inso Bio envisions a future of […]
Bioaesthetics is developing a tissue engineered Nipple-Areolar Complex (NAC) for patients with incomplete or removed NACs due to disease, surgery or birth defects. Bioaesthetics will provide an off-the-shelf-ready, human-derived, acellular NAC graft to plastic and reconstructive surgeons.